ArticleDermatology reports2023
Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.
Article in Dermatology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- Dulaglutide-Associated Lichen Planus Pemphigoides.The Australasian journal of dermatology · 2026Article
- GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives.Pharmaceutics · 2026Review
- Case study on adverse reactions of dulaglutide: literature review.Frontiers in pharmacology · 2026Article
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.Dermatology and therapy · 2025Review
- Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications.Skin appendage disorders · 2025Review
- GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.Advances in therapy · 2025Review
- A Closer Look at the Dermatological Profile of GLP-1 Agonists.Diseases (Basel, Switzerland) · 2025Review
- A Review of Glucagon-like Peptide-1 in Dermatology.The Journal of clinical and aesthetic dermatology · 2025Review
- The first description of mucous membrane pemphigoid induced by enalapril maleate: a case report.BMC oral health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is an autoimmune disease with a chronic relapsing course, predominantly affecting elderly people. Drugs are one of the possible triggers. A class of antidiabetic drugs often associated with the development of BP are inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins), while less known is the association with glucagon-like-peptide-1 receptor agonists. We describe a case of BP caused by dulaglutide and summarize the other few cases described in the literature. As a class of drugs widely used in clinical practice, it is important to know about this possible adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.